A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012

Table 2 MIC ₉₀ (mg/L), antimicrobial susceptibility (%S) and statistically significant changes in susceptibility among resistant pathogen phenotypes

Pathogen	Antimicrobial	MIC₉₀	%S	Significance^a
Gram-positive
E. faecium, VRE (n = 18 [0/18])	AMC	≥16	16.7	N.S.
	AMP	≥32	16.7	N.S.
	LZD	2	100	-
	TIG	0.25	100	-
	VAN	≥64	0.0	-
S. aureus, MRSA (n = 631 [77/554])	LEV	32	13.2	N.S.
	LZD	2	100	-
	MIN	0.5	93.5	p < 0.001 (−)
	PEN	≥16	0.0	-
	TIG	0.25	100	-
	VAN	1	100	-
S. pneumoniae, PRSP (n = 32; 31^b)	AMP	8	0.0	-
	AZI	≥128	19.4	N.S.
	CRO	2	6.3	N.S.
	CLA	≥128	19.4	N.S.
	CLI	≥128	32.3	p < 0.01 (−)
	ERY	≥128	19.4	N.S.
	LEV	2	96.9	N.S.
	LZD	1	100	-
	MER	1	96.9	N.S.
	MIN	≥16	18.8	N.S.
	PEN	4	0.0	-
	VAN	0.5	100	-
Gram-negative
E. coli, ESBL (n = 275 [17/258])	AMK	8	90.5	p < 0.001 (−)
	AMC	32	36.7	p < 0.001 (−)
	AMP	≥64	0.0	-
	CFP	≥64	4.7	N.S.
	CRO	≥128	0.0	-
	IMP	0.5	100	-
	LEV	≥16	37.8	p < 0.01 (−)
	MER	≤0.06	100	-
	PTZ	64	72.4	p < 0.01 (−)
	TIG	0.5	98.9	N.S.
H. influenzae, BL-Pos (n = 269 [32/237])	AMC	2	98.1	N.S.
	AMP	≥64	0.4	N.S.
	CRO	≤0.06	97.4	N.S.
	IMP	1	100	-
	LEV	0.015	100	-
	MER	0.12	100	-
	MIN	1	92.6	N.S.
K. pneumoniae, ESBL (n = 274 [19/255])	AMK	16	85.0	N.S.
	AMC	32	16.1	N.S.
	CFP	≥64	7.3	N.S.
	CRO	≥128	1.8	N.S.
	IMP	0.5	100	N.S.
	LEV	≥16	29.6	N.S.
	MER	0.12	98.4	-
	PTZ	≥256	39.4	N.S.
	TIG	2	78.1	N.S.

^aA negative (−) change in significance indicates an increase in susceptibility; N.S., not significant. A cut-off of p < 0.1 was used for statistical significance testing.
Values given in square parentheses refer to the number of isolates tested against imipenem and meropenem, respectively (and, where different, ampicillin [^b]).
Only seven vancomycin-resistant E. faecalis were collected during this study; data not presented.

ISSN: 2047-2994